Q-omics provides the consensus-scored PRAMEF20 profile across patient tissues and cancer cell-line models. PRAMEF20 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in ACC. Additionally, PRAMEF20 RNA expression shows 6,628 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, and STAD as cancer lineages where PRAMEF20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRAMEF20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRAMEF20 survival associations across molecular data types. PRAMEF20 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRAMEF20 RNA expression–survival associations across cancer types. High PRAMEF20 expression shows unfavorable associations in ACC, UVM, CESC, KIRP and THYM, but favorable associations in ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PRAMEF20 RNA expression.
This table shows molecular features associated with PRAMEF20 in patient tissues and cancer cell lines. In patient samples, PRAMEF20 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PRAMEF20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
